Pulsed Radiofrequency Electromagnetic Field Therapy: A Potential Novel Treatment of Plantar Fasciitis

Brook, Joel; Dauphinée, Damien M; Korpinen, Jaryl; Rawe, Ian

doi:10.1053/j.jfas.2012.01.005

Cited by 31 publications

(40 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, these reductions are consistent with two randomized controlled trials (RCTs) that investigated the efficacy of the ActiPatch medical device in reducing chronic pain. In one such study that investigated the analgesic effect of the medical device for plantar fasciitis pain [27], the reported mean VAS score reduction was 40%, while in the second study that investigated the analgesic effect in osteoarthritis of the knee [26], the reported mean VAS score reduction was 25%.…”

Section: Discussionmentioning

confidence: 99%

“…This 40% figure was chosen to account for a lack of a placebo control and reflects the fact that the two RCTs using this device reported placebo effects of 7 and 3%, respectively [26,27]. Although the understanding of placebo has changed substantially and is now seen as being related to patient's perception of treatment, ways are being investigated to incorporate the placebo effect into medical treatment [30].…”

Section: Discussionmentioning

confidence: 99%

“…One such alternative is the ActiPatch, which is a commercially available medical device in the UK, Canada and parts of Europe that uses pulsed shortwave therapy (PSWT) [25] to provide relief from chronic pain [26,27]. Randomized, double-blind, placebocontrolled studies that utilized the ActiPatch indicate clinically significant decreases in pain, along with a decrease in the use of medication [26][27][28]. For example, in a 4-week study investigating osteoarthritis of the knee [26], 26% of subjects in the ActiPatch treatment group stopped the use of prescribed analgesics, mainly NSAIDs, while 0% added a new therapy for pain management.…”

mentioning

confidence: 99%

See 2 more Smart Citations

An Over-the-Counter Central Sensitization Therapy: A Chronic Back Pain Registry Study of Pain Relief, Medication Use and Their Adverse Effects

2016

View full text Add to dashboard Cite

aim: Back pain, the most prevalent musculoskeletal chronic pain condition, is usually treated with analgesic medications of questionable efficacy and frequent occurrence of adverse side effects. objective: The objective was to determine the effectiveness of the ActiPatch medical devices in reducing chronic back pain, document medication related adverse side effects and establish their impact on quality of life. methods: Upon completing a 7-day trial, subjects were contacted via email with an assessment form using the Constant Contact email program. A total of 1394 responses were collected from subjects who used the device for back pain. Conclusion: Medication adverse effects are common and impact quality of life in the lay population. ActiPatch is an effective intervention for the majority of subjects for treating chronic back pain, although this requires further investigation in randomized clinical trials. • Subjects in this study had chronic back pain (CBP), with a mean pain duration averaging 6.1 years.• Pain etiologies demonstrated a heterogeneous subject population of CBP sufferers.• About 96% of the subjects were using analgesics medications averaging 2.5 per subject, with 71% using prescription analgesics.• The majority of individuals using analgesic medications for CBP report less than adequate pain relief.• Adverse effects from pain medications are common (66%) for CBP sufferers.• CBP sufferers, who report chronic pain for longer than 2 years, also detail using approximately 25% more prescription analgesics than those who have experienced the pain for less than 2 years.• The number of adverse effects is directly proportional to the number of prescription analgesics being used.• The increase in the number of adverse side effects negatively impacts quality of life.• The majority of CBP users, upon using the ActiPatch®, reported a clinically significant reduction in pain within 7 days.• Nearly 50% of the study subjects were able to eliminate or decrease analgesic medications after 7 days of use of the medical device.• The ActiPatch was effective in reducing CBP for the majority of subjects as well as reducing their analgesic use.For reprint orders, please contact: reprints@futuremedicine.com

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

An Over-the-Counter Central Sensitization Therapy: A Chronic Back Pain Registry Study of Pain Relief, Medication Use and Their Adverse Effects

2016

View full text Add to dashboard Cite

show abstract

“…No side effects have been reported. 1,3,4 Several studies have tried to analyze the mechanisms of action behind PEMF therapy. [5][6][7][8][9][10] The treatment alters the electrochemical balance in the cell membrane and interacts with biologic transduction mechanisms.…”

mentioning

confidence: 99%

“…23 PEMF therapy has been used in the field of dentistry as well, with good outcomes in various in vitro, animal, and clinical studies. [24][25][26][27][28][29][30][31] Previously published studies mainly tested large appliances that were not portable 3,32 ; however, smaller, wearable devices are now being manufactured. Little has been written so far about the latter, and the literature only provides a preliminary clinical study that demonstrated that the use of a portable PEMF device coincided with significantly less postoperative pain.…”

mentioning

confidence: 99%

Pulsed electromagnetic fields for postoperative pain: a randomized controlled clinical trial in patients undergoing mandibular third molar extraction

Stocchero

Gobbato

Biagi

et al. 2015

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

View full text Add to dashboard Cite

Pulsed shortwave electromagnetic field therapy increases quality of life in canines with symptoms of osteoarthritics

Sprunks,

McLeod,

Staelin

2024

Veterinary Medicine & Sci

View full text Add to dashboard Cite

BackgroundJoint stiffness, lameness and reduced activity levels are common inflammatory responses observed in canines and have significant impact on quality of life (QOL). The symptoms are often ascribed to osteoarthritis (OA), for which the standard treatment is systemic anti‐inflammatories, but pharmacologic intervention can have significant short‐term and long‐term side effects.ObjectivesTest the efficacy of a Food and Drug Administration (FDA)‐cleared pulsed shortwave therapy (PSWT) device as a means to modulate vagus nerve activity and initiate a systemic anti‐inflammatory response to determine its ability to improve functionality and the QOL of canines with inflammatory symptoms commonly associated with OA.MethodsA randomized, double‐blinded, placebo‐controlled 14‐day study of 60 dogs with a presumptive prior diagnosis of OA in at least one limb joint. Two outcomes assessing changes in the dog's QOL and functionality were measured: subjectively determined changes in eight behaviours associated with discomfort and objectively determined changes in passive range of motion (PROM). The device was secured near the cervico‐thoracic region of the dog's spine. PROM measures were taken at baseline and at the end of study. Behavioural measures were taken daily.ResultsForty‐nine animals completed the study. No negative side effects were reported. Average subjective discomfort scores for the treatment group (N = 26) were reduced from 3.74 to 2.10 (44%), compared to no improvement in the placebo group (N = 23) over the study period (p = 0.0001). Average PROM scores increased by 5.51 (4.59–6.23) degrees relative to the placebo group (p < 0.01). Ninety‐six per cent of the treatment group showed either increased PROM or improved behavioural changes or both, compared to 4% for the placebo group (p < 0.01). Most changes occurred within the first 8 days of treatment.ConclusionsPSWT applied at the level of the cervico‐thoracic spine to target the vagus nerve may have the potential to improve QOL in dogs manifesting behaviours commonly associated with OA.

show abstract

Pulsed Radiofrequency Electromagnetic Field Therapy: A Potential Novel Treatment of Plantar Fasciitis

Cited by 31 publications

References 37 publications

An Over-the-Counter Central Sensitization Therapy: A Chronic Back Pain Registry Study of Pain Relief, Medication Use and Their Adverse Effects

An Over-the-Counter Central Sensitization Therapy: A Chronic Back Pain Registry Study of Pain Relief, Medication Use and Their Adverse Effects

Pulsed electromagnetic fields for postoperative pain: a randomized controlled clinical trial in patients undergoing mandibular third molar extraction

Pulsed shortwave electromagnetic field therapy increases quality of life in canines with symptoms of osteoarthritics

Contact Info

Product

Resources

About